mRNA 1230
Alternative Names: mRNA-1230Latest Information Update: 17 Jul 2024
At a glance
- Originator Moderna Therapeutics
- Class COVID-19 vaccines; Influenza virus vaccines; Respiratory syncytial virus vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I COVID 2019 infections; Influenza virus infections; Respiratory syncytial virus infections
Most Recent Events
- 08 Jul 2024 Moderna's mRNA respiratory vaccine portfolio and Spikevax® market licensed to Mitsubishi Tanabe Pharma Corporation in Japan
- 19 Apr 2023 Moderna Therapeutics completes enrolment in its phase I trial for Influenza virus infections in the USA and Australia
- 13 Apr 2023 Moderna Therapeutics completes enrolment in its phase I trial for Respiratory syncytial virus infections in the USA and Australia